WT1 evaluation in higher-risk myelodysplastic syndrome patients treated with azacitidine

Leuk Lymphoma. 2020 Apr;61(4):979-982. doi: 10.1080/10428194.2019.1699078. Epub 2019 Dec 4.

Authors

Affiliations

¹ Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
² Laboratorio di Neuro-Oncoematologia, Fondazione Santa Lucia, Rome, Italy.
³ Data Center, Fondazione GIMEMA, Rome, Italy.
⁴ Dipartimento Scienze Radiologiche Radioterapiche ed Ematologiche, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Roma.

PMID: 31797711
DOI: 10.1080/10428194.2019.1699078

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antimetabolites, Antineoplastic / therapeutic use
Azacitidine* / therapeutic use
Humans
Myelodysplastic Syndromes* / diagnosis
Myelodysplastic Syndromes* / drug therapy
Myelodysplastic Syndromes* / genetics
WT1 Proteins

Substances

Antimetabolites, Antineoplastic
WT1 Proteins
WT1 protein, human
Azacitidine